Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials

With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients’ tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.

[1]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[2]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Tatiana Popova,et al.  Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data , 2014, Bioinform..

[4]  P. Gestraud,et al.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial , 2014, British Journal of Cancer.

[5]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[6]  Amber M. Johnson,et al.  A decision support framework for genomically informed investigational cancer therapy. , 2015, Journal of the National Cancer Institute.

[7]  C. Cui,et al.  Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma. , 2014, Chinese clinical oncology.

[8]  H. Mudhar Royal College of Pathologists , 1990, The Lancet.

[9]  O. Delattre,et al.  MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. , 2013, Cancer genetics.

[10]  P. Pandolfi,et al.  Haplo‐insufficiency: a driving force in cancer , 2011, The Journal of pathology.

[11]  R. Schilsky,et al.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[13]  Jill P. Mesirov,et al.  Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.

[14]  Jessica N Everett,et al.  Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology , 2014, Journal of Genetic Counseling.

[15]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[16]  Emmanuel Barillot,et al.  Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial , 2014, Front. Genet..

[17]  Doris Berger,et al.  International Cancer Genome Consortium , 2013, Im Focus Onkologie.

[18]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[19]  J. Nunemacher,et al.  Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.

[20]  klaguia International Network of Cancer Genome Projects , 2010 .

[21]  Richard Simon,et al.  Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.

[22]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[23]  Etienne Rouleau,et al.  Guidance for laboratories performing molecular pathology for cancer patients , 2014, Journal of Clinical Pathology.

[24]  B. Tops,et al.  Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe , 2014, Molecular oncology.

[25]  F. Collins,et al.  First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.

[26]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[27]  Razelle Kurzrock,et al.  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.

[28]  S. Sleijfer,et al.  The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[30]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[31]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[32]  R. Mason,et al.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.

[33]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Soria,et al.  From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[36]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[37]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[38]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[39]  Mark Cobbold,et al.  Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study , 2014, PLoS biology.

[40]  J. Salk Clonal evolution in cancer , 2010 .

[41]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[42]  C Sotiriou,et al.  The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.

[43]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[44]  Camile S. Farah,et al.  Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation , 2014, Cancers.

[45]  M. Pestrin,et al.  Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients , 2015, Molecular oncology.

[46]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[47]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[48]  C. Ponting,et al.  Sequencing depth and coverage: key considerations in genomic analyses , 2014, Nature Reviews Genetics.